Curanex Pharmaceuticals regains Nasdaq minimum bid price compliance after reverse split
Curanex Pharmaceuticals said Nasdaq has closed its bid price deficiency matter after the company's stock closed at or above $1.00 for 10 consecutive business days following a 1-for-20 reverse stock split effected August 20, 2026. The company remains listed on The Nasdaq Capital Market, which removes the immediate risk of delisting tied to the low share price.
Key points
- Nasdaq notified the company on November 5, 2025 that its bid price had been below $1.00 for 30 consecutive business days.
- The company effected a 1-for-20 reverse stock split on August 20, 2026.
- On September 3, 2026, Nasdaq confirmed compliance based on closing bid prices from August 20 to September 2, 2026, and closed the matter.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.